- Home
- MGNX vs SND Comparison
MGNX vs SND Comparison
Compare MGNX & SND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- SND
- Stock Information
- Founded
- MGNX 2000
- SND 2011
- Country
- MGNX United States
- SND United States
- Employees
- MGNX N/A
- SND N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- SND Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- MGNX Health Care
- SND Industrials
- Exchange
- MGNX Nasdaq
- SND Nasdaq
- Market Cap
- MGNX 99.7M
- SND 85.0M
- IPO Year
- MGNX 2013
- SND 2016
- Fundamental
- Price
- MGNX $1.82
- SND $2.20
- Analyst Decision
- MGNX Hold
- SND
- Analyst Count
- MGNX 6
- SND 0
- Target Price
- MGNX $3.20
- SND N/A
- AVG Volume (30 Days)
- MGNX 630.9K
- SND 106.8K
- Earning Date
- MGNX 11-04-2025
- SND 11-11-2025
- Dividend Yield
- MGNX N/A
- SND 4.74%
- EPS Growth
- MGNX N/A
- SND N/A
- EPS
- MGNX N/A
- SND 0.02
- Revenue
- MGNX $165,495,000.00
- SND $305,848,000.00
- Revenue This Year
- MGNX N/A
- SND N/A
- Revenue Next Year
- MGNX N/A
- SND N/A
- P/E Ratio
- MGNX N/A
- SND $106.65
- Revenue Growth
- MGNX 303.47
- SND 3.43
- 52 Week Low
- MGNX $0.99
- SND $1.76
- 52 Week High
- MGNX $5.10
- SND $2.80
- Technical
- Relative Strength Index (RSI)
- MGNX 51.87
- SND 58.84
- Support Level
- MGNX $1.69
- SND $2.09
- Resistance Level
- MGNX $1.83
- SND $2.21
- Average True Range (ATR)
- MGNX 0.10
- SND 0.06
- MACD
- MGNX 0.00
- SND -0.00
- Stochastic Oscillator
- MGNX 56.00
- SND 69.43
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.